Javascript must be enabled to continue!
Carboplatin-induced reversible ptosis
View through CrossRef
Neurological side effects have been reported with various chemotherapy drugs, especially platinum derivatives. Ptosis is one such complication which is rarely encountered. We report a case of ptosis and its complete recovery, which had a temporal relation to carboplatin, a platinum-based chemotherapeutic agent. A 48-year-old male patient with colon cancer on carboplatin noticed drooping of the right eyelid after the second cycle of treatment, which worsened gradually in three weeks. Detailed ophthalmological and neurological evaluation was carried out, and no significant association was made. Onset of ptosis correlated with treatment of carboplatin and on reviewing existing literature available diagnosis was made. Over the course of four weeks, the ptosis gradually resolved completely once the carboplatin treatment cycle was completed without the need for surgical intervention. This case highlights the importance of identifying carboplatin as the cause of ptosis and the potential of platinum-based compounds leading to neurological effects. Prompt recognition can lead to complete resolution.
Scientific Scholar
Title: Carboplatin-induced reversible ptosis
Description:
Neurological side effects have been reported with various chemotherapy drugs, especially platinum derivatives.
Ptosis is one such complication which is rarely encountered.
We report a case of ptosis and its complete recovery, which had a temporal relation to carboplatin, a platinum-based chemotherapeutic agent.
A 48-year-old male patient with colon cancer on carboplatin noticed drooping of the right eyelid after the second cycle of treatment, which worsened gradually in three weeks.
Detailed ophthalmological and neurological evaluation was carried out, and no significant association was made.
Onset of ptosis correlated with treatment of carboplatin and on reviewing existing literature available diagnosis was made.
Over the course of four weeks, the ptosis gradually resolved completely once the carboplatin treatment cycle was completed without the need for surgical intervention.
This case highlights the importance of identifying carboplatin as the cause of ptosis and the potential of platinum-based compounds leading to neurological effects.
Prompt recognition can lead to complete resolution.
Related Results
Vincristine‐induced unilateral ptosis
Vincristine‐induced unilateral ptosis
AbstractPurpose To report the ocurrence of an unilateral ptosis in a 2‐year‐old girl treated by vincristine for a vaginal rhabdomyosarcoma.Methods Our young patient developed a vag...
The Association between Refractive Errors and Congenital Ptosis
The Association between Refractive Errors and Congenital Ptosis
Abstract
Background:
Children with congenital ptosis need to be carefully assessed for refractive errors and visual function to identify and trea...
Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non‐small‐cell lung cancer: Is thrombocytopenia predictable?
Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non‐small‐cell lung cancer: Is thrombocytopenia predictable?
AbstractAim: Two 21‐day gemcitabine–carboplatin schedules were evaluated in patients with advanced non‐small cell lung cancer in order to assess the effect of timing of the carbop...
Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicentre analysis
Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicentre analysis
Abstract
BackgroundAlthough concurrent chemoradiotherapy (CCRT) with high-dose cisplatin remains a standard of care for patients with locally advanced nasopharyngeal carcin...
Abstract 1416: Synergistic cytotoxicity of metformin cotreatment with paclitaxel or carboplatin in triple negative breast cancer cell lines
Abstract 1416: Synergistic cytotoxicity of metformin cotreatment with paclitaxel or carboplatin in triple negative breast cancer cell lines
Abstract
Metformin is an oral antidiabetic drug with a putative antineoplastic effect in breast cancer; however, its efficacy in clinical trials has been mixed. Trip...
Abstract 1720: Examining mechanistic underpinnings of chemoresistance in triple negative breast cancer
Abstract 1720: Examining mechanistic underpinnings of chemoresistance in triple negative breast cancer
Abstract
Background: Triple negative breast cancer (TNBC) is not only the most aggressive subtype of breast cancer, but it does also not have many targeted therapeut...
Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models
Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models
Abstract
ARQ087 is a non ATP-competitive tyrosine kinase inhibitor with activity against the FGFR receptor family, and currently in Phase I clinical studies for the ...
Abstract 1716: Mechanisms of resistance in carboplatin, docetaxel and dual drug resistant ovarian cancer cell lines
Abstract 1716: Mechanisms of resistance in carboplatin, docetaxel and dual drug resistant ovarian cancer cell lines
Abstract
Carboplatin and docetaxel are two standard chemotherapeutics used to treat ovarian cancer. Patients often exhibit resistance to single agent therapy, and du...

